Royalty Pharma plc
RPRX
Price:
$26.43
Market Cap:
$11.74B
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematol...[Read more]
Industry
Biotechnology
IPO Date
2020-06-16
Stock Exchange
NASDAQ
Ticker
RPRX
PE Ratio
[10.41]
ROE
[17.37%]
Current Ratio
[1.54]
Dividend Yield
[3.18%]
Enterprise Value
[18.40B]
Dividend History
The ROE as of November 2024 (TTM) for Royalty Pharma plc (RPRX) is 17.37%
According to Royalty Pharma plc’s latest financial reports and current stock price. The company's current ROE is 17.37%. This represents a change of 305.30% compared to the average of 4.29% of the last 4 quarters.
Royalty Pharma plc (RPRX) Historical ROE (quarterly & annually)
How has RPRX ROE performed in the past?
The mean historical ROE of Royalty Pharma plc over the last ten years is 16.99%. The current 17.37% ROE has changed 2.24% with respect to the historical average. Over the past ten years (40 quarters), RPRX's ROE was at its highest in in the December 2019 quarter at 23.26%. The ROE was at its lowest in in the December 2022 quarter at -10.84%.
Average
16.99%
Median
12.73%
Minimum
0.76%
Maximum
38.47%
Royalty Pharma plc (RPRX) ROE by Quarter and Year
Discovering the peaks and valleys of Royalty Pharma plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.18%
Maximum Annual ROE = 38.47%
Minimum Annual Increase = -90.82%
Minimum Annual ROE = 0.76%
| Year | ROE | Change |
|---|---|---|
| 2023 | 17.39% | 2.18% |
| 2022 | 0.76% | -90.82% |
| 2021 | 8.29% | 65.62% |
| 2020 | 5.00% | -86.99% |
| 2019 | 38.47% | 25.31% |
| 2018 | 30.70% | 13.16% |
| 2017 | 27.13% | 113.10% |
| 2016 | 12.73% | 2.39% |
Royalty Pharma plc (RPRX) Average ROE
How has RPRX ROE performed in the past?
The current ROE of Royalty Pharma plc (RPRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
8.81%
5-year avg
13.98%
10-year avg
16.99%
Royalty Pharma plc (RPRX) ROE vs. Peers
How is RPRX’s ROE compared to its peers?
Royalty Pharma plc’s ROE is greater than Prime Medicine, Inc. (-114.95%), greater than Reneo Pharmaceuticals, Inc. (-62.53%), greater than Ginkgo Bioworks Holdings, Inc. (-70.11%), less than Ocean Biomedical, Inc. (64.85%), greater than Adaptive Biotechnologies Corporation (-74.47%), greater than VectivBio Holding AG (-56.92%), greater than Kinnate Biopharma Inc. (-45.17%), greater than Ikena Oncology, Inc. (-39.59%), less than Ascendis Pharma A/S (212.63%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than BeiGene, Ltd. (-25.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Blueprint Medicines Corporation (-47.66%), greater than Iovance Biotherapeutics, Inc. (-58.43%), less than CureVac N.V. (21.40%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than IVERIC bio, Inc. (-39.26%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Day One Biopharmaceuticals, Inc. (-22.40%),
| Company | ROE | Market cap |
|---|---|---|
| -114.95% | $419.71M | |
| -62.53% | $60.84M | |
| -70.11% | $412.70M | |
| 64.85% | $24.95M | |
| -74.47% | $692.15M | |
| -56.92% | $1.06B | |
| -45.17% | $124.99M | |
| -39.59% | $82.52M | |
| 212.63% | $7.76B | |
| -103.92% | $3.83B | |
| -25.12% | $21.35B | |
| -32.52% | $2.28B | |
| -47.66% | $5.98B | |
| -58.43% | $2.61B | |
| 21.40% | $596.65M | |
| -71.78% | $7.58B | |
| -40.45% | $4.12B | |
| -39.26% | $5.51B | |
| -85.39% | $361.25M | |
| -25.23% | $12.60B | |
| -22.40% | $1.38B |
Build a custom stock screener for Royalty Pharma plc (RPRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Royalty Pharma plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Royalty Pharma plc (RPRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Royalty Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Royalty Pharma plc's ROE?
How is the ROE calculated for Royalty Pharma plc (RPRX)?
What is the highest ROE for Royalty Pharma plc (RPRX)?
What is the 3-year average ROE for Royalty Pharma plc (RPRX)?
What is the 5-year average ROE for Royalty Pharma plc (RPRX)?
How does the current ROE for Royalty Pharma plc (RPRX) compare to its historical average?